← Leaderboards
Jeremy H. Herskowitz
Emory University
$5,206,933
Attributed
$9,278,198
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2012–25$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,278,198 · 5
By mechanism
R01$7,963,148 · 2
R00$739,529 · 1
R21$401,101 · 1
K99$174,420 · 1
Top collaborators
- Christopher A. Gaiteri6 shared
- Nicholas Thomas Seyfried6 shared
Most similar at Emory University
Same institution · by research overlap
- Nicholas Thomas Seyfried$21,258,516
- Allan I Levey$89,469,218
- Jingjing Yang$2,460,150
- Peng Jin$28,132,987
- Bing Yao$9,456,110
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposNeuronsPreventDendritic SpinesDementiaInnovationBrainImpaired CognitionS DiseasePathway InteractionsAffectBaseDrug TargetingMouse ModelPathologyMolecularProteinsAutopsyMorphologyExhibitsDisease ProgressionLinkSynapsesTau Proteins
Grant awards (18)
Identifying therapeutic targets that confer synaptic resilience to Alzheimer's disease$800,351
R01 · FY2025 · AG · contact PI
Synaptic Resilience to Tau in Alzheimer's Disease$181,988
R21 · FY2025 · AG · contact PI
Synaptic Resilience to Tau in Alzheimer's Disease$219,113
R21 · FY2024 · AG · contact PI
Identifying therapeutic targets that confer synaptic resilience to Alzheimer's disease$1,050,306
R01 · FY2022 · AG · contact PI
Identifying therapeutic targets that confer synaptic resilience to Alzheimer's disease$1,079,457
R01 · FY2021 · AG · contact PI
Targeting Rho Kinases for Alzheimer's disease Therapeutics$371,250
R01 · FY2021 · AG · contact PI
Identifying therapeutic targets that confer synaptic resilience to Alzheimer's disease$1,019,854
R01 · FY2020 · AG · contact PI
Targeting Rho Kinases for Alzheimer's disease Therapeutics$371,250
R01 · FY2020 · AG · contact PI
Identifying therapeutic targets that confer synaptic resilience to Alzheimer's disease$1,037,676
R01 · FY2019 · AG · contact PI
Targeting Rho Kinases for Alzheimer's disease Therapeutics$371,250
R01 · FY2019 · AG · contact PI
Identifying therapeutic targets that confer synaptic resilience to Alzheimer's disease$1,119,254
R01 · FY2018 · AG · contact PI
Targeting Rho Kinases for Alzheimer's disease Therapeutics$371,250
R01 · FY2018 · AG · contact PI
Targeting Rho Kinases for Alzheimer's disease Therapeutics$371,250
R01 · FY2017 · AG · contact PI
Investigating the RhoA/ROCK pathway for the treatment of Alzheimer's disease$249,000
R00 · FY2016 · AG · contact PI
Investigating the RhoA/ROCK pathway for the treatment of Alzheimer's disease$241,529
R00 · FY2015 · AG · contact PI
Investigating the RhoA/ROCK pathway for the treatment of Alzheimer's disease$249,000
R00 · FY2014 · AG · contact PI
Investigating the RhoA/ROCK pathway for the treatment of Alzheimer's disease$85,590
K99 · FY2013 · AG · contact PI
Investigating the RhoA/ROCK pathway for the treatment of Alzheimer's disease$88,830
K99 · FY2012 · AG · contact PI